<DOC>
	<DOCNO>NCT00149084</DOCNO>
	<brief_summary>The eradication rate standard H. pylori eradication therapy ( triple therapy proton pump inhibitor [ PPI ] , amoxicillin clarithromycin ) depend bacterial susceptibility clarithromycin genotype CYP2C19 patient . The investigator intend investigate whether tailored therapy base two above-mentioned factor increase cure rate initial eradication therapy .</brief_summary>
	<brief_title>Tailored Treatment H. Pylori Infection Based Polymorphisms CYP2C19 23S rRNA H. Pylori</brief_title>
	<detailed_description>Current treatment strategy eradication H. pylorus include proton pump inhibitor ( PPI ) one two anti-bacterial agent , amoxicillin , clarithromycin , metronidazole . PPIs , lansoprazole omeprazole , mainly metabolize liver genetically determine enzyme , S-mephenytoin 4'-hydroxylase ( CYP2C19 ) . Plasma concentration PPIs activity acid inhibition depend significant extent genetic difference activity enzyme . The acid inhibition attain standard dose PPI sometimes therapeutically insufficient individual rapid extensive metabolizer ( RM ) genotype CYP2C19 , whereas individual poor metabolizer ( PM ) genotype CYP2C19 case clinically sufficient . We report CYP2C19 genotype status one determinants H. pylori eradication therapy . In triple therapy PPI , amoxicillin , clarithromycin , bacterial susceptibility clarithromycin well CYP2C19 genotype status significantly relate eradication rate H. pylorus . Therefore , tailor treatment base two factor expect increase eradication rate initial therapy . Interestingly , CYP2C19 genotypes bacterial susceptibility clarithromycin measure genetic test single nucleotide polymorphism ( SNPs ) CYP2C19 gene 23S rRNA gene H. pylorus , respectively . We recently develop inexpensive reliable high-throughput method measurement SNPs invader assay . Polymorphisms CYP2C19 patient mutation 23S rRNA H. pylorus associate susceptibility clarithromycin detect gastric tissue sample infect H. pylorus , gastric tissue sample already use rapid urease test ( RUT ) . Then , treat H. pylori-positive patient tailor regimen base genotype CYP2C19 patient 23S rRNA H. pylorus standard regimen test therapeutic efficacy pharmacogenomics-based tailored strategy prospective manner . Patients randomly assign standard tailor regimen group use computer-generated randomization list base blocked randomization method . Patients assigned standard regimen group treat 30 mg lansoprazole bid , 400 mg clarithromycin bid , 750 mg amoxicillin bid one week , approve Japanese formulary regulation regardless pharmacogenomic background H. pylori-infected peptic ulcer patient . In tailored regimen group , patient infect clarithromycin-sensitive strain H. pylorus treat triple therapy consist clarithromycin 200 mg tid , amoxicillin 500 mg tid individualized dos lansoprazole dose ( i.e. , 30 mg tid RMs , 15 mg tid IMs , 15 mg bid PMs ) one week , patient infect clarithromycin-resistant strain H. pylorus treat dual therapy consist amoxicillin 500 mg qid individualzed dose lansoprazole ( i.e. , 30 mg qid RMs , 15 mg qid IMs , 15 mg bid PMs ) two week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Patients H. pylori infection Patients without H. pylorus infection</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>The tailored H. pylorus eradication therapy</keyword>
	<keyword>CYP2C19 genotype</keyword>
	<keyword>23S rRNA</keyword>
	<keyword>clarithromycin</keyword>
	<keyword>Lansoprazole</keyword>
	<keyword>Amoxicillin</keyword>
	<keyword>H. pylori infection</keyword>
</DOC>